- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01635881
Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
EMERGE: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm Percutaneous Transluminal Coronary Angioplasty (PTCA) Dilatation Catheter
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Piedmont Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Clinical Inclusion Criteria:
- Subject is ≥ 18 years of age.
- Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.
- Subject must agree not to participate in any other clinical study during hospitalization for the index procedure.
- Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia.
Angiographic Inclusion Criteria:
- Subject must have de novo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. An embolic protection device must be used in all Saphenous venous grafts (SVG) interventions performed during the index procedure.
- A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.
- Target and non-target lesions must be located in different coronary arteries or bypass grafts.
- Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may include chronic total occlusions (CTO)
- Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success.
Exclusion Criteria:
- Subject with a known hypersensitivity or contraindication to Aspirin, Heparin, Bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.
- Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours prior to index procedure.
- Subject with known pregnancy or is nursing. Women of childbearing potential should have a documented negative pregnancy test within 7 days before index procedure.
- Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
- A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.
- Cerebrovascular accident (CVA) within the past 6 months.
- Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
- Subject has a known left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary).
Angiographic Exclusion Criteria
- More than two lesions requiring treatment.
- Unprotected left main coronary artery disease.
- Coronary artery spasm of the target vessel in the absence of a significant stenosis.
- Target lesion with angiographic presence of probable or definite thrombus.
- Untreated lesions with >50% diameter stenosis remaining in any coronary artery.
- Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter.
Non-target lesion to be treated during the index procedure meets any of the following criteria:
- Located within a bypass graft (venous or arterial)
- Left main location
- Chronic total occlusion
- Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
- Treatment not deemed a clinical angiographic success
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Emerge
Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
|
The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter. The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device Procedural Success
Time Frame: Peri-procedural
|
Device procedural success consisting of the following:
|
Peri-procedural
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-hospital Major Adverse Cardiac Events (MACE)
Time Frame: Participants will be followed for the duration of hospital stay (an expected average of 24 hours)
|
In-hospital MACE:
|
Participants will be followed for the duration of hospital stay (an expected average of 24 hours)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David E Kandzari, MD, Director, Interventional Cardiology, Chief Scientific Officer, Piedmont Heart Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S2228
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Emerge™ 1.20 mm PTCA Dilatation Catheter
-
Abbott Medical DevicesCompletedIschemic Heart Disease | Coronary Artery Stenosis | Coronary Bypass Graft Stenosis | Chronic Coronary Total OcclusionUnited States
-
AlvimedicaCompletedVascular Diseases | Coronary Artery Disease | Coronary DiseaseTurkey
-
Mauro H. SchenoneNot yet recruitingHypoplastic Left Heart SyndromeUnited States
-
Zhejiang Zylox Medical Device Co., Ltd.CompletedPeripheral Arterial Disease | Popliteal Artery Stenosis | Popliteal Artery Occlusion | Iliac Artery Occlusion | Femoral Artery Occlusion | Iliac Artery Stenosis | Femoral Artery Stenosis
-
Advanced NanoTherapiesMonash University; Cardiovascular Research Foundation, New York; Cogent Technologies...Recruiting
-
Suzhou Zhonghui Medical Technology Co., Ltd.RecruitingPeripheral Arterial DiseaseChina
-
University National Heart HospitalMeril Life Sciences Pvt. Ltd.Recruiting
-
National Taiwan University HospitalUnknownImaging and Interventional Study for Erectile Dysfunction and Lower Urinary Tract Symptoms (PERFECT)Lower Urinary Tract Symptoms | Peripheral Arterial Disease | Erectile DysfunctionTaiwan
-
National Taiwan University HospitalM.A. Med Alliance S.A.RecruitingPeripheral Arterial Disease | Erectile Dysfunction | Arterial StenosisTaiwan